Insulin Resistance in Women With Prolactinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00481299 |
Recruitment Status
:
Completed
First Posted
: June 1, 2007
Last Update Posted
: June 1, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma.
The purpose of the protocol was to evaluate cardiovascular disease risk factors in women with prolactinoma treated with dopamine agonists and to study the influence of disease control and anthropometry on their metabolic profile.
Condition or disease |
---|
Prolactinoma Insulin Resistance Hyperlipidemia |
Study Type : | Observational |
Actual Enrollment : | 2004 participants |
Observational Model: | Defined Population |
Primary Purpose: | Screening |
Time Perspective: | Cross-Sectional |
Time Perspective: | Prospective |
Official Title: | Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists |
Study Start Date : | October 2004 |
Actual Study Completion Date : | September 2006 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 48 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Prolactinoma
- Female gender
- Premenopausal
Exclusion Criteria:
- Obesity (BMI ≥ 30 kg/m²)
- Diabetes mellitus
- Hypertension
- GH deficiency
- Hypothyroidism
- Primary hypogonadism
- Adrenal insufficiency
- Pituitary surgery

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00481299
Brazil | |
Clementino Fraga Filho University Hospital | |
Rio de Janeiro, RJ, Brazil |
Principal Investigator: | Erika CO Naliato, MSc | Federal University of Rio de Janeiro - Brazil |
ClinicalTrials.gov Identifier: | NCT00481299 History of Changes |
Other Study ID Numbers: |
178/04 |
First Posted: | June 1, 2007 Key Record Dates |
Last Update Posted: | June 1, 2007 |
Last Verified: | April 2007 |
Keywords provided by Universidade Federal do Rio de Janeiro:
Insulin glucose lipids prolactinoma hyperprolactinemia |
Additional relevant MeSH terms:
Insulin Resistance Hyperlipidemias Hyperlipoproteinemias Prolactinoma Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Dyslipidemias Lipid Metabolism Disorders Adenoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |
Pituitary Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Pituitary Diseases Hypothalamic Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Endocrine System Diseases Insulin Hypoglycemic Agents Physiological Effects of Drugs |